La maladie de Lyme : Vers un nouveau vaccin ?

Details

Supervisors

Van Bambeke, Françoise

Faculty

Faculté de pharmacie et des sciences biomédicales

Degree label

Master [120] en sciences pharmaceutiques, à finalité spécialisée

Abstract

enLyme disease is caused by a spirochete of the genus Borrelia, transmitted by ticks. This disease is increasingly common in the Northern Hemisphere. It can cause significant complications (joint, cardiac or nervous system). Although there was a vaccine against it in the early 2000s, none is currently available on the market. The medical need for a new vaccine is therefore increasing day by day in order to prevent the population against this disease. A candidate vaccine is currently under development. It is a phase 2 clinical assay. This master thesis begins with a reminder on Lyme disease and the mechanisms of Borrelia infection to present antigens considered usable for vaccination. Next, the former vaccine LYMErix™ is reviewed to understand its benefits, limitations and causes of his remove from the market. Finally, several studies about the niew vaccine VLA15 are detailed in order to focus on scientific advances and propose new research perspectives for this vaccine.